Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28200676 | 0.87 | LAP3 (0.36) | LAP3TSHRMETAP1 | |
| SCHEMBL28201243 | 0.85 | TSHR (0.52) | LAP3TSHRCYP3A4L3MBTL1 | |
| SCHEMBL242469 | 0.79 | — | — | |
| SCHEMBL27780195 | 0.77 | LAP3 (0.46) | LAP3METAP1SMPD1 | |
| SCHEMBL10877493 | 0.77 | LAP3 (0.46) | LAP3METAP1SMPD1 | |
| SCHEMBL11333556 | 0.75 | CYP3A4 (0.44) | LAP3METAP1SMPD1CYP3A4L3MBTL1 | |
| SCHEMBL28813 | 0.74 | LAP3 (0.50) | LAP3SMPD1 | |
| SCHEMBL13735694 | 0.72 | LAP3 (0.52) | LAP3SMPD1 | |
| SCHEMBL907146 | 0.71 | TSHR (0.38) | LAP3TSHRCYP3A4L3MBTL1 | |
| SCHEMBL485994 | 0.69 | TSHR (0.36) | LAP3TSHRMETAP1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353124-A1 | DERMAL FILLER COMPOSITIONS FOR FINE LINE TREATMENT | ALLERGAN INDUSTRIE, SAS (FR) | 2020-11-12 | — | — | US | claimed |
| US-20200139006-A1 | DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS | ALLERGAN IND SAS (FR) | 2020-05-07 | — | — | US | claimed |
| US-9328347-B2 | siRNA useful in the treatment of flavivirus infection | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-05-03 | — | — | US | claimed |
| US-20140248336-A1 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2014-09-04 | — | — | US | claimed |
| WO-2013012835-A2 | SIRNA USEFUL IN THE TREATMENT OF FLAVIVIRUS INFECTION | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-01-24 | — | — | WO | claimed |
| US-20250297251-A1 | CERTAIN DUX4 INHIBITORS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250263699-A1 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH siRNAS TARGETING TBX3 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-21 | — | — | US | disclosed |
| US-20250257361-A1 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH SIRNAS TARGETING SMYD2 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-14 | — | — | US | disclosed |
| US-20250236868-A1 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH SIRNAS TARGETING CIDEB | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-24 | — | — | US | disclosed |
| US-20250228885-A1 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH SIRNAS TARGETING GPAM | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-17 | — | — | US | disclosed |
| WO-2025038613-A1 | THERAPEUTIC MODULATION OF SNORA13 FOR TREATMENT OF RIBOSOMOPATHIES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4504746-A2 | COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES WITH SIRNAS TARGETING CIDEB | The Board of Regents of the University of Texas System (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2010105149-A1 | ESTER GELS, METHODS OF MANUFACTURE, AND USES THEREOF | JEEN INTERNATIONAL CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20090297461-A1 | Personal Care and Dermatologic Compositions | PERLE ADAM | 2009-12-03 | — | — | US | disclosed |
| EP-1998737-A2 | PERSONAL CARE AND DERMATOLOGIC COMPOSITIONS | Perle, Adam (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007100689-A2 | PERSONAL CARE AND DERMATOLOGIC COMPOSITIONS | PERLE ADAM (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20060039986-A1 | Functional material, process for producing functional material and functional member and environment modifying apparatus using the functional material | KABUSHIKI KAISHA ERUBU (JP) | 2006-02-23 | — | — | US | disclosed |
| CN-1087292-C | Sulfonyloxadiazolones | BAYER AG (DE) | 2002-07-10 | — | — | CN | disclosed |
| US-6045992-A | Reverse transcriptase detection and inhibition | CITY OF HOPE (US) | 2000-04-04 | — | — | US | disclosed |
| US-5708154-A | RNA-DNA hybrid molecules of nucleic acid | CITY OF HOPE (US) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090297461-A1 | Personal Care and Dermatologic Compositions | CUTA, DPM1, DSG1 | LAP3 4104/4885TSHR 3421/4885METAP1 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.